1
|
Cameron MC, Lee E, Hibler BP, Barker CA,
Mori S, Cordova M, Nehal KS and Rossi A: Basal cell carcinoma:
Epidemiology; pathophysiology; clinical and histological subtypes;
and disease associations. J Am Acad Dermatol. 80:303–317.
2019.PubMed/NCBI View Article : Google Scholar
|
2
|
Likhacheva A, Awan M, Barker CA, Bhatnagar
A, Bradfield L, Brady MS, Buzurovic I, Geiger JL, Parvathaneni U,
Zaky S and Devlin PM: Definitive and postoperative radiation
therapy for basal and squamous cell cancers of the skin: Executive
summary of an American society for radiation oncology clinical
practice guideline. Pract Radiat Oncol. 10:8–20. 2020.PubMed/NCBI View Article : Google Scholar
|
3
|
Wilder RB, Kittelson JM and Shimm DS:
Basal cell carcinoma treated with radiation therapy. Cancer.
68:2134–2137. 1991.PubMed/NCBI View Article : Google Scholar
|
4
|
Armstrong P, Martin S and Lask G: Sonic
hedgehog pathway inhibition in the treatment of advanced basal cell
carcinoma. In: Biologic and Systemic Agents in Dermatology.
Springer, Cham, pp541-548, 2018.
|
5
|
Sekulic A, Migden MR, Oro AE, Dirix L,
Lewis KD, Hainsworth JD, Solomon JA, Yoo S, Arron ST, Friedlander
PA, et al: Efficacy and safety of vismodegib in advanced basal-cell
carcinoma. N Engl J Med. 366:2171–2179. 2012.PubMed/NCBI View Article : Google Scholar
|
6
|
Sekulic A, Migden MR, Lewis K, Hainsworth
JD, Solomon JA, Yoo S, Arron ST, Friedlander PA, Marmur E, Rudin
CM, et al: Pivotal ERIVANCE basal cell carcinoma (BCC) study:
12-month update of efficacy and safety of vismodegib in advanced
BCC. J Am Acad Dermatol. 72:1021–1026.e8. 2015.PubMed/NCBI View Article : Google Scholar
|
7
|
Hehlgans S, Booms P, Güllülü Ö, Sader R,
Rödel C, Balermpas P, Rödel F and Ghanaati S: Radiation
sensitization of basal cell and head and neck squamous cell
carcinoma by the hedgehog pathway inhibitor vismodegib. Int J Mol
Sci. 19(2485)2018.PubMed/NCBI View Article : Google Scholar
|
8
|
Franco AI, Eastwick G, Farah R, Heyboer M,
Lee M and Aridgides P: Upfront radiotherapy with concurrent and
adjuvant vismodegib is effective and well-tolerated in a patient
with advanced, multifocal basal cell carcinoma. Case Rep Dermatol
Med. 2018(2354146)2018.PubMed/NCBI View Article : Google Scholar
|
9
|
Pollom EL, Bui TT, Chang AL, Colevas AD
and Hara WY: Concurrent vismodegib and radiotherapy for recurrent,
advanced basal cell carcinoma. JAMA Dermatol. 151:998–1001.
2015.PubMed/NCBI View Article : Google Scholar
|
10
|
Block AM, Alite F, Diaz AZ, Borrowdale RW,
Clark JI and Choi M: Combination trimodality therapy using
vismodegib for basal cell carcinoma of the face. Case Rep Oncol
Med. 2015(827608)2015.PubMed/NCBI View Article : Google Scholar
|
11
|
Gathings RM, Orscheln CS and Huang WW:
Compassionate use of vismodegib and adjuvant radiotherapy in the
treatment of multiple locally advanced and inoperable basal cell
carcinomas and squamous cell carcinomas of the skin. J Am Acad
Dermatol. 70:e88–e89. 2014.PubMed/NCBI View Article : Google Scholar
|
12
|
Zeng J, Aziz K, Chettiar ST, Aftab BT,
Armour M, Gajula R, Gandhi N, Salih T, Herman JM, Wong J, et al:
Hedgehog pathway inhibition radiosensitizes non-small cell lung
cancers. Int J Radiat Oncol Biol Phys. 86:143–149. 2013.PubMed/NCBI View Article : Google Scholar
|
13
|
Le H, Kleinerman R, Lerman OZ, Brown D,
Galiano R, Gurtner GC, Warren SM, Levine JP and Saadeh PB: Hedgehog
signaling is essential for normal wound healing. Wound Repair
Regen. 16:768–773. 2008.PubMed/NCBI View Article : Google Scholar
|
14
|
ClinicalTrials.gov: Phase II Study of Radiation
Therapy and Vismodegib for Advanced Head/Neck Basal Cell Carcinoma.
ClinicalTrials.gov Identifier: NCT01835626. https://clinicaltrials.gov/ct2/show/NCT01835626. Last
updated October 5, 2020.
|